Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Amgen, J&J Anemia Drugs Won’t Face New U.S. Coverage Policy

Amgen Inc. and Johnson & Johnson won’t face new reimbursement limits for their anemia medicines after U.S. regulators decided against issuing a national coverage policy.

The Centers for Medicare and Medicaid Services proposed in March to maintain current standards for using Amgen’s Aranesp and Epogen and J&J’s Procrit, leaving coverage determination to regional Medicare contractors that process reimbursement claims. The agency made the proposal final today.

“Given the totality of the currently available evidence, CMS will not issue a national coverage determination at this time,” the agency said on its website.

The decision removes an “overhang” on shares of Thousand Oaks, California-based Amgen, said Michael Yee, an analyst with RBC Capital Markets, in a research note last week. Maintaining the coverage policy won’t affect revenue at the company, the world’s largest biotechnology firm, he said.

“There simply, and rationally, isn’t enough info at this time to change current treatment guidelines,” Yee, based in San Francisco, wrote in a June 9 note to clients.

J&J, the world’s second-biggest seller of health-care products after New York-based Pfizer Inc., is based in New Brunswick, New Jersey.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.